<DOC>
	<DOCNO>NCT01944033</DOCNO>
	<brief_summary>The effectiveness β2-agonists treatment exacerbation COPD already establish . The purpose study compare effectiveness β2-agonists alone nebulization association β2-agonists + Ipratropium bromide treatment acute exacerbation COPD consult emergency departement base clinical aarterial blood gas .</brief_summary>
	<brief_title>β2-agonist Versus Ipratropium Bromide Associated With β2-agonists Chronic Obstructive Pulmonary Disease Exacerbation</brief_title>
	<detailed_description>It prospective study randomize practiced patient consult emergency departement acute exacerbation COPD . The patient divide two group : Group AB ; receive β2-agonists + Ipratropium bromide nebulization Group B receive β2-agonists alone nebulization )</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>know suspect COPD base pulmonary function test , arterial blood gas , clinical history , physical examination , chest radiograph Age 18 year old . COPD Exacerbation : FR &gt; 25c/min PaCO2 &gt; 6Kpa PH &lt; 7,35 SaO2 &lt; 90 % GCS ≤ 12 hypersensitivity anticholinergic severe acidosis lack patient cooperation serious heart arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>β2-agonist</keyword>
	<keyword>Ipratropium Bromide</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease Exacerbation</keyword>
	<keyword>Emergency departement</keyword>
</DOC>